British Columbia, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CSE: ATT / OTC:ATTBF) is pleased to announce that it has completed the sale (the "Sale") of its 35% interest in Northern Vine Canada Inc. ("Northern Vine") to Emerald Health Therapeutics, Inc. (TSXV:EMH / OTCQX:EMHTF) ("Emerald") in exchange for $2 million in cash and $4 million in common shares of Emerald, 50% of which are free trading and 50% of which may be sold in 30 days.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.